MDSAML

Quiz

Quiz: Is This Monotherapy Safe, Well-Tolerated in Newly Diagnosed AML?

01/20/2022

According to data from a phase 2b study, which of the following therapies is generally safe and effective as a first-line therapy for AML patients who are unfit for intensive chemotherapy?

According to data from a phase...

01/20/2022

Oncology

News

Aspacytarabine is Safe, Well-Tolerated for Patients With Newly Diagnosed AML

01/20/2022

Data from a phase 2b study on aspacytarabine, a prodrug of cytarabine, as a single agent for induction and consolidation therapy for patients with newly diagnosed AML who are unfit for standard induction chemotherapy, were presented at the...

Data from a phase 2b study on...

01/20/2022

Oncology

Test Your Knowledge

Quiz: Does This Monotherapy Induce High CR/CRi Rates in AML?

01/10/2022

True or false: Gilteritinib monotherapy induces a high CR/CRi rate in older newly-diagnosed patients with FLT3-mutated AML.

True or false: Gilteritinib...

01/10/2022

Oncology

News

Gilteritinib Monotherapy Induces High Rate of Complete Response in FLT3-Mutated AML

01/10/2022

Data from the phase 2/1b sub-study of the Beat AML Master Trial were presented at the 2021 ASH Annual Meeting and assessed the efficacy of gilteritinib monotherapy with the addition of decitabine in non-responders in older newly diagnosed...

Data from the phase 2/1b...

01/10/2022

Oncology

Videos

Dr Lee Highlights the Treatment Landscape for Patients With MDS, AML

11/29/2021

Sangmin Lee, MD, highlights the current treatment landscape for patients with MDS, including novel therapies that are in development in combination with hypomethylating agents.

Sangmin Lee, MD, highlights the...

11/29/2021

Oncology